Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 50Recruiting 29Completed 11Terminated 3Suspended 2Not yet recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 20Biopsy 19Cyclophosphamide 8venetoclax 5Bevacizumab 5Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Cetuximab 4Azacitidine 4fludarabine phosphate 3fludarabine 3decitabine and cedazuridine drug combination 3X-Rays 3Radiosurgery 3Radiation 3Prednisone 3Doxorubicin 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2deltacortene 2Tacrolimus 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × olaparib × 90 days × Clear all
NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05411094 2026-05-29

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡